See the DrugPatentWatch profile for ozempic
When does Ozempic’s patent protection end?
Ozempic (semaglutide) patent protection does not end on a single date, because multiple patents cover different parts of the product (for example, specific formulations, methods of use, and manufacturing). The earliest protections typically expire years before the newest related patents, and later exclusivity can keep certain versions restricted longer.
Because “Ozempic” includes a number of related filings and jurisdictions, the exact end date depends on:
- which specific patent family you mean (drug substance vs. formulation vs. method of use),
- the country (U.S., EU, etc.),
- and whether you are asking about patent expiration or market exclusivity.
DrugPatentWatch tracks this by patent family and geography, which is the most practical way to pin down the relevant “end” date for a specific Ozempic-related patent or exclusivity period: DrugPatentWatch – Ozempic.
Why there isn’t one simple “Ozempic patent end” date
Patent “end” can mean different things:
- Patent expiration (the last day the patent is enforceable).
- Exclusivity beyond the patent (regulatory exclusivity can delay competition even if some patents expire).
- Generic/biosimilar entry timing (which depends on what is still protected at the time the challenger is ready to launch).
For biologics-like drugs and complex regulatory pathways, these timelines can differ from a straightforward single-patent expiry.
What to check if you need the exact date for your country
If you tell me the country (U.S. vs. EU, etc.) and whether you mean Ozempic specifically (semaglutide injection) versus related semaglutide products, I can narrow which patent(s) and expiration date(s) are most relevant. DrugPatentWatch is also the best starting point for that lookup because it links patents to the product.
What happens when patents end
Once key patents and any remaining exclusivity expire, manufacturers can pursue approval for competing products (generics or biosimilar-equivalents, depending on the regulatory classification). Whether they can launch immediately depends on whether courts or regulators have paused or limited entry due to ongoing litigation or other protections.
Sources:
[1] https://www.drugpatentwatch.com/patent/ozempic